HRK

Across TCGA pan-cancer cohorts, HRK mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated HRK data layer compared with 26 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher HRK mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated HRK expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

HNSC, GBM, and LUAD are the cancer types where HRK mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.449	1.000	.033	4	view →
GBM	OS	Tertile	All	0.554	1.000	.018	1	view →
LUAD	OS	Median	All	1.000	0.926	.017	1	view →
PDAC	DFS	Median	II,III,IV	0.681	0.777	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

HRK–HNSC (OS)

Open the HNSC breakdown →